• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

DRC: The Ministry of Health and DNDi launch a project designed to facilitate access to new treatments against sleeping sickness

Home > Press releases

DRC: The Ministry of Health and DNDi launch a project designed to facilitate access to new treatments against sleeping sickness

Young boy with healthcare worker at hospital setting
Kinshasa — 29 Sep 2020
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • English
    • English
    • Français

The objective of the World Bank-funded project is to eliminate the neglected tropical disease.

An ambitious programme to strengthen diagnostic and community outreach capacities, designed to facilitate access to medicines and eliminate sleeping sickness (human African trypanosomiasis) in the Democratic Republic of the Congo (DRC), was approved by the Ministry of Health’sHealth System Strengthening for Better Maternal and Child Health Results Project (PDSS).

This project will be implemented by the Swiss medical research NGO, DNDi (Drugs for Neglected Diseases initiative), in close collaboration with the National Sleeping Sickness Control Programme (NSSCP). The project’s budget is USD 2.5 million (4.9 billion Congolese francs), provided by the World Bank through PDSS.

The project was officially launched this Tuesday in Kinshasa by Dr Cleophas If Malaba, Acting Secretary General for Health, in the presence of Mr Chirac Bulanga Milemba, DNDi’s Country Operations Manager in the DRC, and Dr Dominique Baabo Kubuya, PDSS coordinator, as well as several other sleeping sickness control partners in the DRC.

De gauche à droite: Dr Dominique Baabo Kubuya, coordinateur du PDSS; M. Chirac Bulanga Milemba, chef du bureau pays de DNDi en RDC; Dr If Malaba Cleophas, le Secrétaire Général à la Santé l’intérim; Dr Eric Miyaka, directeur du PNLTHA,
From left to right: Dr Dominique Baabo Kubuya, PDSS coordinator; M. Chirac Bulanga Milemba, DNDi‘s Country Operations Manager in DRC; Dr Cleophas If Malaba, Acting Secretary General for Health; Dr Eric Miyaka, Director of PNLTHA

Following clinical trials conducted by DNDi and its partners, the very first oral treatment for sleeping sickness – the effective, easy-to-administer, and well tolerated new drug fexinidazole – received marketing authorisation in the DRC in December 2018.

“Although considerable progress has been made over the past few years in human African trypanosomiasis control, much remains to be done. A new drug, even if it is revolutionary, is of no use if people do not come in for testing,” explained Mr Chirac Bulanga Milemba. “Thus, this project will help improve access to screening and healthcare tools for the communities most affected by this life-threatening disease. This is a crucial step towards achieving complete elimination of sleeping sickness in the DRC.”

In the absence of treatment, sleeping sickness is usually fatal. Almost 8.5 million people in Africa face a moderate to very high risk of infection. The DRC accounts for the majority of cases, with almost 85% of notified cases.

The project will last 16 months. It will facilitate patient access to medicines by strengthening diagnostic capacities in 14 health zones in six provinces: Kwilu, Maï-Ndombe, Western Kasai, Kasai, Central Kasai, and Lomami.

“Extensive outreach to local communities will also be conducted to raise awareness of the dangers associated with sleeping sickness, and to inform them of the existence of the new fexinidazole treatment, available at no cost in the healthcare system of the affected regions,” explained Dr Dominique Baabo Kubuya, PDSS coordinator.

 Dr Dominique Baabo Kubuya, coordinateur du PDSS
Dr Dominique Baabo Kubuya, PDSS coordinator

In his speech delivered during the launch of the project, the Acting Secretary General for Health, Dr Cleophas If Malaba, highlighted the Ministry of Health’s determination to improve the country’s healthcare system, reiterating that this is one of the government’s priorities.

DNDi will collaborate with the Ministry of Health through the NSSCP, the provincial health authorities, the National Institute of Medical Research (INRB), and several partners, including the Institute of Tropical Medicine Antwerp, to strengthen the sleeping sickness control capacities of local health systems; strengthen community engagement in sleeping sickness monitoring and control; and circulate knowledge related to the sleeping sickness programme activities.

Over 400 health workers will receive training in screening and case management. In the 14 health zones, 80% of the target population will have access to a sleeping sickness test performed less than 5 km from their home. The objective is to triple the proportion of patients (from 15 to 45%) who decide to go of their own accord to a health facility for screening.

The project will run through 15 December 2021.

About PDSS

The Health System Strengthening for Better Maternal and Child Health Results Project (PDSS) is a public health project created in 2015 by the government of the Democratic Republic of the Congo (DRC) to increase the efficiency and efficacy of the health system and improve human development outcomes.

About DNDi 

DNDi (The Drugs for Neglected Diseases initiative (DNDi) in a non-profit medical research organisation established in 2003 by Médecins Sans Frontières to address the needs of patients suffering from neglected diseases. Since its inception, DNDi has developed treatments for malaria, sleeping sickness, Chagas disease, leishmaniasis, and paediatric HIV. It recently participated in the launch of a coalition to accelerate research on COVID-19 in low- and middle-income countries. DNDi would like to thank all of its donors, public and private, who support its work and who have helped fund the research which led to the development of fexinidazole.

About sleeping sickness

Sleeping sickness, or human African trypanosomiasis, is usually fatal without treatment. Transmitted by the bite of a tsetse fly, following a period with nonspecific symptoms, it evolves to cause neuropsychiatric symptoms, including abnormal behaviour, and a debilitating disruption of sleep patterns that have given this neglected disease its name. About 8.5 million people in sub-Saharan Africa are at moderate to very high risk.

Media contacts

In Kinshasa: Sandrine Francine Ngalula francinengal@gmail.com 

In Geneva: Frédéric Ojardias fojardias@dndi.org

Photo credit: Kenny Mbala-DNDi

Funding Registration & access Sleeping sickness

Read, watch, share

Loading...
Woman standing in front of a house
Press releases
2 Feb 2023

Dutch government renews support to DNDi projects on poverty-related diseases that disproportionately impact women

Statements
1 Feb 2023

DNDi interventions at the 152nd session of the WHO Executive Board

Young man sitting in hospital setting
News
25 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

Child receiving treatment
News
20 Jan 2023

DNDi’s 20th year of bringing the best science for the most neglected

Child affected by dengue and her mother at their home in Bangkok, Thailand.
Stories
16 Dec 2022

2022: Six advances in neglected disease research to remember

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo